Clinical Trial Update: PCV10 Reactogenicity and Immunogenicity Study - Malindi [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing reactogenicity and immunogenicity of PCV10 in Malindi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Pneumonia

Drugs mentioned

• PCV10 (pneumococcal 10-valent conjugate vaccine)

Snippet

Sponsor: KEMRI-Wellcome Trust Collaborative Research Program | Conditions: Pneumococcal Pneumonia | Phase 4 | Status: UNKNOWN